Desafíos en el uso de agonistas del receptor GLP-1: accesibilidad, uso fuera de indicación y propuestas para el futuro

Authors

  • Jorge Hernández Universidad de Santander, Bucaramanga, Colombia. https://orcid.org/0009-0001-5758-5965
  • Luis Dulcey Universidad de los Andes, Mérida, Venezuela.
  • Jaime Gómez Universidad de los Andes, Mérida, Venezuela.
  • Juan Therán Universidad de Santander, Bucaramanga, Colombia.

DOI:

https://doi.org/10.20453/rmh.v36i4.6242

Downloads

Download data is not yet available.

Author Biographies

Jorge Hernández, Universidad de Santander, Bucaramanga, Colombia.

m

Luis Dulcey, Universidad de los Andes, Mérida, Venezuela.

-

Jaime Gómez, Universidad de los Andes, Mérida, Venezuela.

n

Juan Therán, Universidad de Santander, Bucaramanga, Colombia.

m

References

Silva Pacheco de Moraes D, Estrin MA. GLP-1 receptor agonists for weight loss, benefits and risks: A systematic review of the literature. Salud, Ciencia y Tecnología – Serie de Conferencias [Internet]. 2024 Sep 18 [citado el 25 de enero de 2025];3:719. doi: 10.56294/sctconf2024.719. Disponible en: https://conferencias.ageditor.ar/index.php/sctconf/article/view/719

Mottl AK, Nicholas SB. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2024 Mar 1; 83(3):277–287. doi: 10.1053/j.ajkd.2023.09.003.

Chen X, Zhang X, Xiang X, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2024; 16:251. doi: 10.1186/s13098-024-01497-4.

Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL, Kalyani RR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1; 76(9):1117–1145. doi: 10.1016/j.jacc.2020.06.017.

Khan DA, Banerji A, Blumenthal KG, Phillips EJ, Solensky R, White AA, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022 Dec 1; 150(6):1333–1393. doi: 10.1016/j.jaci.2022.08.028.

Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022 Nov 1; 163(5):1198–1225. doi: 10.1053/j.gastro.2022.08.045.

Lee HA, Kim HY. Therapeutic mechanisms and clinical effects of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci. 2023 Jun 1; 24(11):9324. doi: 10.3390/ijms24119324.

Downloads

Published

2025-12-19

How to Cite

1.
Hernández J, Dulcey L, Gómez J, Therán J. Desafíos en el uso de agonistas del receptor GLP-1: accesibilidad, uso fuera de indicación y propuestas para el futuro. Rev Méd Hered [Internet]. 2025 Dec. 19 [cited 2025 Dec. 27];36(4):387-8. Available from: https://revistas.upch.edu.pe/index.php/RMH/article/view/6242

Issue

Vol. 36 No. 4 (2025): Octubre-diciembre

Section

LETTER

License

Copyright (c) 2025 Los autores

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors assign their rights to the RMH so that may disseminate the article through the means at their disposal. The journal will provide forms of affidavit of authorship and authorization for the publication of the article, which shall be submitted with the manuscript. Authors retain the right to share, copy, distribute, perform and publicly communicate their article, or part of it, mentioning the original publication in the journal.